<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151383</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2208</org_study_id>
    <secondary_id>2013-002847-28</secondary_id>
    <nct_id>NCT02151383</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics &amp; Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure</brief_title>
  <acronym>RELAX-PEDS-PK</acronym>
  <official_title>Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to &lt;18 Years of Age, Hospitalized With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of an
      intravenous infusion of serelaxin on top of standard of care therapy, in pediatric patients
      with acute heart failure (AHF)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated based on results from pivotal adult AHF study CRLX030A2301
  </why_stopped>
  <start_date type="Actual">September 5, 2014</start_date>
  <completion_date type="Actual">April 3, 2017</completion_date>
  <primary_completion_date type="Actual">April 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients reported with adverse events, serious adverse events and death</measure>
    <time_frame>through 28 days</time_frame>
    <description>Number of patients with adverse events (including confirmed systolic blood pressure decreases and worsening heart failure), serious adverse events and death will be analyzed in order to evaluate the safety and tolerability of intravenous serelaxin in AHF patients. Adverse events will be assessed by signs/symptoms, clinical laboratory and electrocardiographs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Css (steady state concentration)</measure>
    <time_frame>at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: CL (clearance)</measure>
    <time_frame>at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of arterial BP</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of central venous pressure (CVP)</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of left atrial pressure (LAP)</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of pulmonary artery pressure (PAP- systolic and diastolic)</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of central venous and arterial oxygen saturation</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of urine output</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of blood lactate levels</measure>
    <time_frame>baseline, prior to each dose escalation, and at 24 hr. post end of infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Serelaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serelaxin will be administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <description>Serelaxin will be administered intravenously for up to 48 hours.</description>
    <arm_group_label>Serelaxin</arm_group_label>
    <other_name>RLX030</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Body weight ≥2.5 kg to ≤120 kg

          -  Hospitalized in an intensive care unit or step-down unit with the following:

          -  - Signs and symptoms of acute heart failure of any etiology

          -  - Stable dose of vasoactive and/or inotropic drugs

          -  - For non-surgical patients echocardiographic evidence of reduced ventricular function
             (ejection fraction &lt;50% or fractional shortening &lt;28%)

          -  Systolic blood pressure (SBP) ≥25th percentile SBP for age and gender.

        EXCLUSION CRITERIA:

          -  Moderate to severe left ventricular outflow tract, mitral stenosis, or aortic arch
             obstruction

          -  Single ventricle physiology

          -  Fixed pulmonary hypertension

          -  Blood lactate levels &gt;5 mmol/L at screening

          -  Birth &lt; 36 weeks post-conceptual age (for patients &lt;1year old)

          -  Confirmed or clinically suspected systemic infection or severe localized infection

          -  Dyspnea or acute lung injury primarily due to non-cardiac causes

          -  Patients with severe renal impairment, those known to have significant renal disease
             and those having renal replacement therapy

          -  High use of inotropic and/or vasoactive agents at screening

          -  Electrocardiographic abnormalities

          -  Solid organ transplant recipient within 1 year of transplantation or one who presents
             with severe organ rejection

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute heart failure,</keyword>
  <keyword>RELAX−AHF−PEDIATRIC PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>September 27, 2017</submitted>
    <returned>October 25, 2017</returned>
    <submitted>March 5, 2018</submitted>
    <returned>April 2, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

